HomeCompareVXTRF vs ABBV

VXTRF vs ABBV: Dividend Comparison 2026

VXTRF yields 6666666.89% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 VXTRF wins by $8.25874132811738e+44M in total portfolio value
10 years
VXTRF
VXTRF
● Live price
6666666.89%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$8.25874132811738e+44M
Annual income
$825,849,764,240,280,500,000,000,000,000,000,000,000,000,000,000,000.00
Full VXTRF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — VXTRF vs ABBV

📍 VXTRF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodVXTRFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, VXTRF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
VXTRF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

VXTRF
Annual income on $10K today (after 15% tax)
$566,666,685.56/yr
After 10yr DRIP, annual income (after tax)
$701,972,299,604,238,500,000,000,000,000,000,000,000,000,000,000,000.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, VXTRF beats the other by $701,972,299,604,238,500,000,000,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of VXTRF + ABBV for your $10,000?

VXTRF: 50%ABBV: 50%
100% ABBV50/50100% VXTRF
Portfolio after 10yr
$4.12937066405869e+44M
Annual income
$412,924,882,120,140,300,000,000,000,000,000,000,000,000,000,000,000.00/yr
Blended yield
100.00%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

VXTRF
No analyst data
Altman Z
-17.5
Piotroski
3/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

VXTRF buys
0
ABBV buys
0
No recent congressional trades found for VXTRF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricVXTRFABBV
Forward yield6666666.89%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$8.25874132811738e+44M$102.3K
Annual income after 10y$825,849,764,240,280,500,000,000,000,000,000,000,000,000,000,000,000.00$24,771.77
Total dividends collected$8.258725385650417e+44M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: VXTRF vs ABBV ($10,000, DRIP)

YearVXTRF PortfolioVXTRF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$666,677,389$666,666,688.89$11,550$430.00+$666.67MVXTRF
2$41,538,246,747,390$41,537,533,402,583.80$13,472$627.96+$41538246.73MVXTRF
3$2,418,785,420,797,992,400$2,418,740,974,873,972,700.00$15,906$926.08+$2418785420797.98MVXTRF
4$131,632,552,731,528,880,000,000$131,629,964,631,128,620,000,000.00$19,071$1,382.55+$131632552731528880.00MVXTRF
5$6,694,930,685,222,868,000,000,000,000$6,694,789,838,391,446,000,000,000,000.00$23,302$2,095.81+$6.694930685222867e+21MVXTRF
6$318,233,377,594,375,670,000,000,000,000,000$318,226,214,018,542,420,000,000,000,000,000.00$29,150$3,237.93+$3.182333775943757e+26MVXTRF
7$14,137,163,415,533,200,000,000,000,000,000,000,000$14,136,822,905,819,175,000,000,000,000,000,000,000.00$37,536$5,121.41+$1.4137163415533202e+31MVXTRF
8$586,942,804,196,016,000,000,000,000,000,000,000,000,000$586,927,677,431,161,500,000,000,000,000,000,000,000,000.00$50,079$8,338.38+$5.86942804196016e+35MVXTRF
9$22,774,365,847,992,805,000,000,000,000,000,000,000,000,000,000$22,773,737,819,192,316,000,000,000,000,000,000,000,000,000,000.00$69,753$14,065.80+$2.2774365847992803e+40MVXTRF
10$825,874,132,811,737,900,000,000,000,000,000,000,000,000,000,000,000$825,849,764,240,280,500,000,000,000,000,000,000,000,000,000,000,000.00$102,337$24,771.77+$8.25874132811738e+44MVXTRF

VXTRF vs ABBV: Complete Analysis 2026

VXTRFStock

Voxtur Analytics Corp. operates as a real estate technology company. The company provides automated workflows and targeted data analytics to simplify tax solutions, property valuation, and settlement services for investors, lenders, government agencies, and mortgage servicers. Its solutions include Voxtur Assessment, Voxtur Valuation, Voxtur Settlement Services, and Voxtur Data & Insights. The company offers software that automates and digitizes the appraisal process, including order tracking, job assignment, collaboration, scheduling tools, and mobile apps for appraisers and enterprises; desktop review software for assessors and government agencies that generates customized portals to view multiple elements related to a property, including street level imagery, aerial imagery, building outline sketches, advanced mapping tools, property valuation details, comparable property analysis, and structural characteristics; software that analyzes the accuracy of property assessments to deliver comparable modeling and predictive valuations using proprietary algorithms; and real estate valuation solutions to deliver appraisal and broker price opinion services. It also provides property tax analysis and appeal management platform and sketch software; outsourced property-related services; real estate technology and non-legal default services; and full service title, escrow, and closing services. In addition, the company commercializes client data through the delivery of reports and individual data requests; and customized reports. It serves property lending and property tax sectors in the United States and Canada. The company was formerly known as iLOOKABOUT Corp. and changed its name to Voxtur Analytics Corp. in February 2021. Voxtur Analytics Corp. is headquartered in London, Canada.

Full VXTRF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this VXTRF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

VXTRF vs SCHDVXTRF vs JEPIVXTRF vs OVXTRF vs KOVXTRF vs MAINVXTRF vs JNJVXTRF vs MRKVXTRF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.